Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

UPDATE 3-Cheaper Roche drug as good as Lucentis-report

Stock MarketsApr 27, 2011 10:52PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

* Study results could eat into sales of pricier Roche drug

* Avastin costs about $50/shot vs about $2,000 for Lucentis

(Add timeline for results in second paragraph)

By Julie Steenhuysen

CHICAGO, April 27 (Reuters) - Avastin, a cancer drug made by Roche Holding AG , was about as effective as the company's far more expensive eye drug, Lucentis, at preventing vision loss in people with age-related macular degeneration, the New York Times reported on Wednesday.

The two drugs were compared in a federally funded U.S. study due to be released on Sunday at a medical meeting and in the New England Journal of Medicine. The results are now expected some time on Thursday. [ID:nLDE73J1XO]

The Times report cited two anonymous sources who said the study found injections of Lucentis and Avastin given every four weeks had similar results after one year. Release of trial results ahead of their publication is considered a scientific and ethical breach.

At stake are billions of dollars in Lucentis sales for both Roche, which sells the medicine in the U.S., and Novartis Inc , which sells the medicine outside the United States.

Avastin could cannibalize Lucentis sales because it costs about $50 per shot, compared with about $2,000 for a dose of Lucentis and would be a more attractive treatment if its efficacy and safety profiles are similar.

Age related macular degeneration, or AMD, is the leading cause of blindness in people over 60. Some 13 million Americans have signs of AMD and more than 1 million Americans have the wet form, the most severe type.

Avastin is not licensed for use in the eye but it works in a similar way to Lucentis, and doctors often use Avastin off label in these patients.

Most analysts expected Avastin to prove as effective as Lucentis in the 1,200-patient test.

Last year, Roche and Novartis each generated around $1.5 billion in Lucentis sales and some analysts suggest it could go on to become a $10 billion-plus drug.


The New York Times said researchers taking part in the study met on Tuesday in Chicago to hear the results, but were sworn to secrecy. The study was conducted by the National Eye Institute, part of the National Institutes of Health.

NEI spokeswoman Jean Horrigan confirmed that the meeting took place but could not comment on whether the institute will investigate who leaked the results, or when they would become available.

What the study may not settle is a growing debate over whether using a cancer drug to treat an eye disease exposes patients to additional safety risks.

Yaron Werber of Citigroup said in a note to clients on Wednesday the study is too small to detect any safety differences between the two drugs, echoing claims by Roche's Genentech unit.

Anthony Adamis, global head of ophthalmology at Genentech, said in an interview this week there is an emerging body of data suggesting there may be safety differences between the two molecules. Genentech has not seen the results of the full study.

Adamis said Lucentis is a much smaller molecule than Avastin and is cleared out of the blood stream within two hours, as opposed to Avastin, which takes 20 days to be cleared.

"The thinking is that would be a good thing because the more it is exposed to the body the greater the risk for side effects," Adamis said.

Some analysts believe there may be an increased risk of stroke and death with Avastin because it does not bind as tightly to the eye and could cause systemic side effects.

The outcome of the U.S. trial is important not only for the two Swiss drugmakers but also Germany's Bayer , which is developing a rival eye drug called VEGF Trap-Eye with Regeneron .

In the wet form of macular degeneration, abnormal blood vessels grow beneath the retina and leak blood and fluid. Both Lucentis and Avastin are vascular endothelial growth factor, or VEGF, inhibitors that work by blocking the growth of blood vessels. (Editing by Michele Gershberg, Bernard Orr, and Lincoln Feast)

UPDATE 3-Cheaper Roche drug as good as Lucentis-report

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email